Announcing WuXiBody™ - A New Bispecific Antibody Technology Platform

WuXi Biologics Appoints Harvard Professor David R. Liu to Scientific Advisory Board

WuXi Biologics’ Chief Quality Officer Received Foreign Post Service Award from FDA

WuXi Biologics Commenced Process Validation
in MFG2
WuXi Biologics and Inhibrx Enter an Exclusive Partnership for GMP Manufacturing

I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs

WuXi Biologics and Immune Pharmaceuticals Announce Late-Phase Development and Manufacturing Partnership for a First-In-Class Monoclonal Antibody

WuXi Biologics and Harbour BioMed Announce Strategic Development and Manufacturing Partnership
WuXi Biologics Selected into the Hang Seng HK 35 Index

WuXi Biologics Reports Robust 2018 Interim Results
October 17 - 18, 2018
November 5 - 7, 2018
November 12 - 15, 2018